Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Raw Materials (2023 - 2026)

Adagio Medical Holdings has reported Raw Materials over the past 4 years, most recently at $1.4 million for Q1 2026.

  • Quarterly Raw Materials fell 11.54% to $1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Mar 2026, down 11.54% year-over-year, with the annual reading at $1.4 million for FY2025, 15.45% down from the prior year.
  • Raw Materials was $1.4 million for Q1 2026 at Adagio Medical Holdings, down from $1.4 million in the prior quarter.
  • Over five years, Raw Materials peaked at $2.5 million in Q3 2024 and troughed at $1.4 million in Q1 2026.
  • The 4-year median for Raw Materials is $1.6 million (2025), against an average of $1.7 million.
  • Year-over-year, Raw Materials crashed 45.15% in 2025 and then decreased 11.54% in 2026.
  • A 4-year view of Raw Materials shows it stood at $2.2 million in 2023, then fell by 23.88% to $1.7 million in 2024, then fell by 15.45% to $1.4 million in 2025, then fell by 4.15% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for ADGM's Raw Materials are $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025).